NDA Accepted for Dymista for Allergic Rhinitis

The FDA has accepted for filing the NDA for Dymista (azelastine HCl and fluticasone propionate; Meda) nasal spray for the treatment of allergic rhinitis. Efficacy and safety of Dymista has been demonstrated in several studies involving over 4,000 patients, including a long-term safety study involving over 600 patients.

For more information call (732) 564-2200 or visit www.medapharma.us